PharmaSources/XuanyaoFebruary 25, 2019
Tag: Drugs , biological , global
Secondly, the distribution of the top 10 types of biological drugs is shown in Fig. 2.
近10年全球上市生物药类型TOP10分布 | Distribution of Top 10 Types of Global Biological Drugs Marketed in Recent Decade |
数量 | Quantity |
疫苗制剂 | Vaccine formulation |
完整抗体 | Complete antibody |
重组细胞因子 | Recombinant cytokine |
血液提取物 | Blood extract |
重组生物酶 | Recombinant biological enzyme |
重组激素 | Recombinant hormone |
融合蛋白 | Fusion protein |
重组凝血因子 | Recombinant coagulation factor |
细胞疗法 | Cell therapy |
重组多肽 | Recombinant polypeptide |
Research and marketed varieties of antibody drugs have been hot in recent years, however, vaccine formulations have been the biological drug with the largest quantity marketed in recent decade in the world. New vaccines are one of the key fields of the biomedicine industry in China, and the frequent negative vaccine events have raised higher requirements for vaccine development and manufacturing enterprises. The cervical cancer vaccine marketed overseas has eventually been marketed in China, however, it is still an imported drug. We look forward to the rapid strengthening of R&D of Chinese-produced vaccines, to break the monopoly of imported drugs in the future.
Antibody drug family mainly consists of monoclonal antibodies, which are specific drugs against tumors and characterized by strong targeting, high specificity, and low toxic and side effects. The global market concentration of antibody drugs is very high: Roche, AbbVie, J & J, and Amgen, the top 4 by market share, occupy a total of 60.5% market share, however, the marketing of two Chinese-produced anti-PD-1 drugs and many anti-PD-1/PD-L1 drugs to be marketed in the future give the Chinese people great confidence, and the low-cost high-quality antibody drugs bring hopes to more Chinese families.
In recent decade, recombinant cytokines produced using genetic engineering techniques in the world have good efficacy in treating tumors, hematopoietic disorders, and infections, etc. as biological response modifier. The marketing of the first-in-class new biological drug: Recombinant Cytokine Gene Derived Protein Injection ("Novaferon") in 2018 has brought more choices to the large population of hepatitis B patients in China.
Finally, let’s see the distribution of top 10 therapeutic areas.
近10年全球上市生物药治疗领域前十分布 | Distribution of Top 10 Therapeutic Areas of Global Biological Drugs Marketed in Recent Decade |
数量 | Quantity |
感染性疾病 | Infectious diseases |
肿瘤 | Tumors |
内分泌和代谢疾病 | Endocrine and metabolic disorders |
血液系统疾病 | Hematological system diseases |
免疫系统疾病 | Immune system diseases |
神经系统疾病 | Nervous system diseases |
肌肉骨骼和结缔组织疾病 | Musculoskeletal and connective tissue diseases |
皮肤病 | Skin diseases |
消化系统疾病 | Digestive system disease |
眼部疾病 | Eye diseases |
We can see from the figure that the new drugs in recent decade were focused on the infectious diseases, tumors, endocrine and metabolic disorders, hematological system diseases, and immune system diseases.
Drugs for infectious diseases mainly consist of antivirals and vaccines. Speaking of vaccines, the Chinese virologist Gu Fangzhou took the lead in successfully developing the Live-Attenuated Poliomyelitis Vaccine in Dragee Candy in 1962, which, after its popularization in China in 1964, reduced the annual average incidence of polio from the 0.00406% in 1949 to 0.000046% in 1993 and prevented hundreds of thousands of children from disability. Let’s honor the memory of Mr. Gu!
Oncology has been one of the fields with the fastest market capacity growth in recent years, which many pharmaceutical enterprises and online medical supply companies have laid out. The quantity of biological drugs in tumor therapeutic area may be in the top position in the next decade. More and more people are likely to suffer cancers with the increase of life expectancy. Chemical drugs do not lead to satisfactory effects in tumor treatment, while precision medicine and the rapidly developing biological drugs have been increasingly recognized by doctors and patients.
Is it a little confusing that cardiovascular and cerebrovascular drugs were not among the top 10 therapeutic areas of biological drugs marketed in recent decade? Why were there no biological drugs in such a large field? The ratio between the chemical drugs and biological drugs marketed in the cardiovascular and cerebrovascular field was 5:1 in recent decade. What were the reasons for such a wide gap? We’ll talk about it in my next article.
References:
Back to read:
Author Biography
Xuanyao, an independent observer of the pharmaceutical industry, with a master’s degree in Pharmacology from China Pharmaceutical University; having successively served in the Market Department of a listed pharmaceutical enterprise in China and Marketing Department of a Global 500 foreign enterprise; currently engaging in the pharmaceutical private equity investment industry, with the WeChat account: pharmacology_cpu
-----------------------------------------------------------------------
Editor's Note:
To apply for becoming a contributor of En-CPhI.cn,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@ubmsinoexpo.com.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: